{"title": "2023 Biological Approvals", "author": "Center; Research", "url": "https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2023-biological-approvals", "hostname": "fda.gov", "description": "Information about the 2023 Biological Approvals", "sitename": "FDA", "date": "2023-02-17", "cleaned_text": "2023 Biological Approvals The Center for Biologics Evaluation and Research (CBER) regulates products under a variety of regulatory authorities. See the Development & Approval Process page for a description of what products are approved as Biologics License Applications (BLAs), Premarket Approvals (PMAs), New Drug Applications (NDAs) or 510Ks. Biologics License Applications and Supplements New BLAs (except those for blood banking), and BLA supplements that are expected to significantly enhance the public health (e.g., for new/expanded indications, new routes of administration, new dosage formulations and improved safety). [2023 Biological License Application Approvals](/vaccines-blood-biologics/development-approval-process-cber/2023-biological-license-application-approvals) [2023 Biological License Application Supplement Noteworthy Approvals](/vaccines-blood-biologics/development-approval-process-cber/2023-biological-license-application-supplement-noteworthy-approvals) Other Applications Approved or Cleared by the Center for Biologics Evaluation and Research (CBER) Medical devices involved in the collection, processing, testing, manufacture and administration of licensed blood, blood components and cellular products. "}